| 摘要 |
<P>PROBLEM TO BE SOLVED: To provide a novel peptide capable of enhancing immune response activity in a patient having such a risk that the patient may be attacked by a MAGE related tumor, such as a melanoma. <P>SOLUTION: A human MAGE-1 protein and the peptide are provided, respectively, wherein the peptide is derived from a region consisting of 58 amino acids at a C-terminal of an MAGE-1 antigen. A DNA vector encoding the MAGE-1 protein is transformed into a host, then the MAGE-1 protein is expressed and recovered. The peptide and a vaccine composition are each administered for the purpose of inducing cytotoxic T lymphocyte (CTL) response effective for a MAGE supporting tumor. The peptide is administered to a patient of 70 kg in an amount of about 1.0 μg to about 500 μg as an general range, then the administered amount is controlled according to response and state of the patient. A pharmacological composition for therapeutic treatment is used parenterally, locally, perorally or topically, and is preferably used, for example, intravenously, hypodermically or intramuscularly. <P>COPYRIGHT: (C)2004,JPO |
